59,466 results match your criteria hepatitis associated

Analysis of the vaccination status of older adults.

Rev Esc Enferm USP 2021 18;55:e03723. Epub 2021 Jun 18.

Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil.

Objective: To describe the sociodemographic characteristics, functional capacity and vaccination status of older adults, and to verify the factors associated with the incomplete vaccination status and the absence of the vaccination card.

Method: Cross-sectional and analytical study conducted with older adults living in the city of Uberaba (MG). The following analyzes were carried out: descriptive, bivariate and multinomial logistic regression (p<0. Read More

View Article and Full-Text PDF

Episode of Hepatitis C viral infection in the people of Swat, Pakistan.

Braz J Biol 2021 21;82:e243283. Epub 2021 Jun 21.

Center for Animal Sciences & Fisheries, University of Swat, Swat, Pakistan.

Infectious agents cause serious diseases in humans worldwide and are responsible for the high rate of morbidity and mortality. The prevalence and epidemiology of infectious disease (HCV) in the hospital visited patients referred by the physicians through the initial findings and their associated risk factors were studied in Swat. The data of 174 infected patients were collected during the period of 2015 to 2017 from two clinical laboratories of Tehsil Matta Swat. Read More

View Article and Full-Text PDF

Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.

Drugs 2021 Jun 23. Epub 2021 Jun 23.

Division of Hematology and Medical Oncology, and Oncology Clinical Pharmacist, OHSU Hospital and Clinics, Portland, OR, USA.

The thrombopoietin receptor agonists (TPO-RAs) romiplostim, eltrombopag, avatrombopag, and lusutrombopag carry unique US Food and Drug Administration (US FDA)- and European Medicines Agency (EMA)-approved indications and may be used to increase platelet counts in a variety of conditions. Current indications for available TPO-RAs include treatment of chronic immune thrombocytopenia (ITP) in cases of insufficient response to prior treatment (avatrombopag, eltrombopag, romiplostim), management of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure (avatrombopag, lusutrombopag), management of severe aplastic anemia (eltrombopag), and management of thrombocytopenia associated with interferon-based therapy for hepatitis C (eltrombopag). Across current indications, pharmacists can assist in stabilizing platelet counts and help to reduce large undulations commonly seen when starting, stopping, or transitioning between these agents. Read More

View Article and Full-Text PDF

Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States.

J Immigr Minor Health 2021 Jun 23. Epub 2021 Jun 23.

Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA, USA.

Tuberculosis (TB) and chronic hepatitis B virus (CHB) infection can be prevented with treatment and vaccination, respectively. We reviewed epidemiology and guidelines for TB and CHB to inform strategies for reducing United States (U.S. Read More

View Article and Full-Text PDF

Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa.

J Infect Dis 2021 Jun 23. Epub 2021 Jun 23.

Division of Digestive Diseases, Department of Metabolism, Digestion & Reproduction, Imperial College London, UK.

Background: Prevalence of occult hepatitis B infection (OBI) and its clinical outcomes have been poorly studied in Africa.

Method: Using the PROLIFICA cohort, we compared the prevalence of OBI between HBsAg-negative healthy adults screened from the general population (controls) and HBsAg-negative patients with advanced liver disease (cases) and estimated the population attributable fraction for the effect of OBI on advanced liver disease.

Results: OBI prevalence was significantly higher among the cases (15/82, 18. Read More

View Article and Full-Text PDF

Aplastic Anemia Frequency and Management in Pediatric Liver Transplantations Due to Non-A-E Hepatitis.

Turk J Gastroenterol 2021 Mar;32(3):313-317

Department of Pediatric Gastroenterology, Hepatology and Nutrition, Ege University School of Medicine, İzmir, Turkey.

Background: Hepatitis-associated aplastic anemia (HAAA) is a rare complication that presented with bone marrow failure after acute hepatitis. HAAA usually occurs in adolescent men within 1-6 months following hepatitis. Most of HAAA's etiology has non-A-E viral hepatitis. Read More

View Article and Full-Text PDF

Hepatitis B and syphilis prevalence and risk factors of transmission among febrile patients in a primary health facility in Kogi State, Nigeria.

J Immunoassay Immunochem 2021 Jun 23:1-9. Epub 2021 Jun 23.

Department of Microbiology, Kogi State University, Kogi State, Nigeria.

Hepatitis B and syphilis remained a global disease with a worrisome prevalence in Nigeria. This study was to determine their prevalence and factors associated with HBV and syphilis infection in febrile patients in Ejule metropolis, Nigeria. In a cross-sectional study, sera obtained from the patients were screened for HBsAg (HBV) and syphilis using commercial immunoassay kits. Read More

View Article and Full-Text PDF

Quercetin as a protective agent for liver diseases: A comprehensive descriptive review of the molecular mechanism.

Phytother Res 2021 Jun 22. Epub 2021 Jun 22.

State Key Laboratory of Southwestern Chinese Medicine Resources, Ministry of Education, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Quercetin is the major representative of the flavonoid subgroup of flavones, with good pharmacological activities for the treatment of liver diseases, including liver steatosis, fatty hepatitis, liver fibrosis, and liver cancer. It can significantly influence the development of liver diseases via multiple targets and multiple pathways via antifat accumulation, anti-inflammatory, and antioxidant activity, as well as the inhibition of cellular apoptosis and proliferation. Despite extensive research on understanding the mechanism of quercetin in the treatment of liver diseases, there are still no targeted therapies available. Read More

View Article and Full-Text PDF

Preventing Infectious Complications of Immunomodulation in COVID-19 in Foreign-Born Patients.

J Immigr Minor Health 2021 Jun 22. Epub 2021 Jun 22.

Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.

Immunomodulating therapies for COVID-19 may carry risks of reactivating latent infections in foreign-born people. We conducted a rapid review of infection-related complications of immunomodulatory therapies for COVID-19. We convened a committee of specialists to formulate a screening and management strategy for latent infections in our setting. Read More

View Article and Full-Text PDF

Age-dependence of hypervirulent fowl adenovirus type 4 pathogenicity in specific-pathogen-free chickens.

Poult Sci 2021 May 8;100(8):101238. Epub 2021 May 8.

College of Veterinary Medicine, Yangzhou University, Yangzhou, China; Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, China. Electronic address:

Hypervirulent fowl adenovirus serotype 4 (hvFAdV-4) has emerged as a major pathogen of hepatitis-hydropericardium syndrome (HHS) with increased mortality in chickens, resulting in economic losses to the Chinese poultry industry since June 2015. Here, we isolated a hypervirulent FAdV-4 (hvFAdV-4) strain (designated GD616) from 25-day-old meat-type chickens with severe HHS in Guangdong Province China in June 2017. The whole genome of the strain GD616 shares high homology with those in the recently-reported hvFAdV-4 isolates in China, with natural deletions of ORF19 and ORF27. Read More

View Article and Full-Text PDF

Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy.

Aliment Pharmacol Ther 2021 Jun 22. Epub 2021 Jun 22.

Guangzhou, China.

Background: Obesity is typically associated with metabolic dysfunction, but its impact on hepatocellular carcinoma (HCC) remains unclear in patients with chronic hepatitis B (CHB).

Aim: To study the effect of obesity on HCC development in patients with CHB receiving antiviral therapy.

Methods: We included patients from a Chinese multicentre, prospective, observational, treated CHB cohort in this study. Read More

View Article and Full-Text PDF

Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18-70 years from three countries.

PLoS One 2021 22;16(6):e0253005. Epub 2021 Jun 22.

Center for Infection Research in Cancer, Moffitt Cancer Center, Tampa, Florida, United States of America.

Objectives: To estimate the seroprevalence of Chlamydia trachomatis (CT), herpes simplex type-2 (HSV2), hepatitis C (HCV), Epstein-Barr virus (EBV) and nine human papilloma virus (HPV) types, and investigated factors associated with the seropositivity among men from three countries (Brazil, Mexico and U.S).

Methods: Archived serum specimens collected at enrollment for n = 600 men were tested for antibodies against CT, HSV2, HCV, EBV, and 9-valent HPV vaccine types (6/11/16/18/31/33/45/52/58) using multiplex serologic assays. Read More

View Article and Full-Text PDF

The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis.

PLoS One 2021 22;16(6):e0251570. Epub 2021 Jun 22.

Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Background: Due to its invasive procedure patients on hemodialysis (HD) are at high risk of infections. Infections acquired in dialysis units can prolong hospitalization date and/or prolong illness in patients, and increase treatment cost. There are no adequate data on the prevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections in HD patients. Read More

View Article and Full-Text PDF

New therapies for hepatitis delta virus infection.

Liver Int 2021 06;41 Suppl 1:30-37

Centre de recherche sur l'inflammation, Université de Paris, Inserm, CNRS, Paris, France.

Hepatitis delta virus (HDV) infection is a defective virus requiring hepatitis B virus (HBV) for its complete replication cycle. HDV is a small hepatotropic RNA virus and around 15 to 25 million people worldwide are living with chronic hepatitis delta (CHD) infection. However, the prevalence of HDV may be underestimated, and screening is frequently insufficient. Read More

View Article and Full-Text PDF

Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.

Liver Int 2021 06;41 Suppl 1:9-14

Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Chronic hepatitis B virus (HBV) infection remains an important global health problem, and may be difficult to manage in clinical practice. Nucleos(t)ide analogues (NAs) with a high barrier to resistance (entecavir [ETV], tenofovir disoproxil fumarate [TDF] and tenofovir alafenamide [TAF]) are the most frequently used HBV treatments because of their long-term effectiveness and tolerability. ETV may be less effective in patients with lamivudine-resistant strains, and TDF is associated with impaired renal function and reductions in bone mineral density. Read More

View Article and Full-Text PDF

Is hepatitis delta underestimated?

Liver Int 2021 06;41 Suppl 1:38-44

Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece.

Hepatitis D virus may be underestimated because it is a significant problem in HBsAg-positive patients, especially those who inject drugs, have HIV or HCV co-infections and/or live in certain endemic regions. In the past few decades, the prevalence of HDV was expected to have decreased as a result of improvements in public healthcare policies and universal HBV vaccination programs. However, HDV has continued to spread in low-income countries, with local outbreaks and migration to less endemic areas, so that its prevalence has remained stable or even increased in certain regions. Read More

View Article and Full-Text PDF

Is elimination of HCV realistic by 2030: France.

Liver Int 2021 06;41 Suppl 1:45-49

Université Paris Centre, Département d'Hépatologie, Hôpital Cochin, APHP; INSERM U1223, Institut Pasteur, Paris, France.

The World Health Organization (WHO) has proposed a plan for the elimination of viral hepatitis with a goal of reducing new hepatitis infections by 30% and 90% in 2020 and 2030, and associated mortality by 10% and 65% respectively. Actions and targets to reach these goals include improving hepatitis B virus (HBV) vaccination programs, the prevention of mother-to-child transmission of HBV, improving the safety of blood products and injections, risk reduction policies and optimizing the diagnosis and treatment of hepatitis. The goal of eliminating hepatitis C virus (HCV) by 2030 is based on three main actions: increased screening, strengthening access to care and the prevention of infections and re-infections. Read More

View Article and Full-Text PDF

Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes.

Nutr Metab Cardiovasc Dis 2021 May 26. Epub 2021 May 26.

Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy. Electronic address:

Liver health is a key determinant of cardiovascular risk (CVR). Hepatic fibrosis is the shared common result of chronic hepatitis, irrespective of aetiology. Fibrosis profoundly distorts liver tissue architecture and perturbs hepatic physiology, dictates the course of chronic liver disease and is increasingly recognized as a CVR factor. Read More

View Article and Full-Text PDF

Sero-molecular epidemiology of hepatitis E virus in pigs and human contacts in Ghana.

One Health Outlook 2021 Jun 22;3(1):13. Epub 2021 Jun 22.

Institute of Virology, Charite, Berlin, Germany.

Background: Hepatitis E virus (HEV) is among the leading causes of viral hepatitis in most developing countries. Zoonotic acquisition of HEV genotype 3 from swine has come into focus more recently. Available studies on HEV in Ghana and other countries in the region do not provide enough information towards understanding the epidemiology of HEV in human and animal populations. Read More

View Article and Full-Text PDF

Progesterone-Mediated Enhancement of Hepatitis E Virus Replication in Human Liver Cells.

mBio 2021 Jun 22:e0143421. Epub 2021 Jun 22.

Center for Emerging, Zoonotic and Arthropod-borne Pathogens, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA.

Progesterone is crucial for the maintenance of pregnancy. During pregnancy hepatitis E virus (HEV) infection is associated with increased fulminant hepatic failure and mortality rates. In this study, we determined whether progesterone modulates HEV replication and HEV-induced innate cytokine response in Huh7-S10-3 human liver cells. Read More

View Article and Full-Text PDF

Inferior cure rate in pilot study of four-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.

Liver Int 2021 Jun 21. Epub 2021 Jun 21.

Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.

Background & Aims: Shortening the treatment duration for chronic hepatitis C may increase feasibility and reduce cost of cure. The aims of this study were to compare four weeks of glecaprevir/pibrentasvir (GLE/PIB) treatment with and without ribavirin for patients with chronic hepatitis C and favorable baseline characteristics, and to monitor the development of resistance-associated substitutions (RAS) and re-treatment outcomes if treatment failed.

Methods: We performed an open-label single center randomized controlled trial, in which patients with chronic hepatitis C were randomized 1:1 to GLE/PIB +/- ribavirin, stratified by genotype 3. Read More

View Article and Full-Text PDF

Genetic polymorphisms of chemokine (C-X-C motif) ligand 10 gene associated with hepatitis B virus infection in a Chinese Han population.

Int Immunopharmacol 2021 Jun 18;98:107888. Epub 2021 Jun 18.

Department of Epidemiology, School of Public Health and Management, Chongqing Medical University, Chongqing, China. Electronic address:

Background And Aims: Chemokine (C-X-C motif) ligand 10 (CXCL10) has been recently shown to be associated with inflammatory diseases. However, the association between the genetic variation of this gene and the susceptibility to hepatitis B virus (HBV) infection remains unclear, especially in children. This study aimed to investigate the relationship between CXCL10 polymorphisms and the risk of chronic HBV infection in a Chinese Han population. Read More

View Article and Full-Text PDF

Exploration and time-serial validation of logistic regression models composed of multiple laboratory tests for early detection of HCV-associated hepatocellular carcinoma.

Clin Chim Acta 2021 Jun 18. Epub 2021 Jun 18.

Department of Medical Informatics & Decision Sciences, Yamaguchi University, Graduate School of Medicine, Ube, Yamaguchi, Japan. Electronic address:

Background: We developed a laboratory test-based regression model for early detection of hepatocellular carcinoma (HCC) associated with HCV in its surveillance.

Methods: This matched case-control study was conducted by enrolling 452 patients with chronic hepatitis and/or cirrhosis, including 129 patients complicated with HCC. One-to-one propensity score matching was performed by referring to sex, age, and fibrosis-4 index, which resulted in 102 patients each in HCC and non-HCC groups. Read More

View Article and Full-Text PDF

Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.

Hepatol Int 2021 Jun 21. Epub 2021 Jun 21.

Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102, Hong Kong, China.

Background: Concomitant chronic hepatitis B infection (CHB) and non-alcoholic fatty liver disease (NAFLD) is common, but the implications of NAFLD on clinical outcomes of CHB, including hepatocellular carcinoma (HCC), are not well-investigated.

Methods: CHB patients were recruited for transient elastography assessment for liver stiffness (LS), and controlled attenuation parameter (CAP), a non-invasive quantification of hepatic steatosis, and were prospectively followed up for development of HCC. Steatosis and severe steatosis were diagnosed by CAP ≥ 248 dB/m and ≥ 280 dB/m respectively, and advanced fibrosis/cirrhosis was diagnosed by LS ≥ 9 kPa. Read More

View Article and Full-Text PDF

Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.

Pharmacol Res Perspect 2021 Aug;9(4):e00811

Internal Medicine Division, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.

This study aimed to investigate the efficacy and safety of sofosbuvir-based therapies for the treatment of cirrhosis from hepatitis C virus (HCV) genotype 2 infection. Data of all consecutive HCV genotype 2 cirrhotic patients who started sofosbuvir-based treatments between January 2015 and March 2017 in eight Italian tertiary hospitals were collected retrospectively. Overall, 273 patients (Child A: 94. Read More

View Article and Full-Text PDF

Serum HBV pregenomic RNA exhibited opposite associations with NKdim and NKbright cell immunity in treatment-naïve chronic hepatitis B patients.

Biosci Rep 2021 Jun 21. Epub 2021 Jun 21.

Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Hepatitis B virus (HBV) pregenomic RNA (pgRNA) is a new biomarker that reflects HBV replication, but its relationship with natural killer (NK) cell immunity in chronic hepatitis B (CHB) is unknown. We assessed serum HBV pgRNA levels in 323 CHB patients by reverse transcription-polymerase chain reaction, assessed cytokine production and activation and inhibitory markers of NK cells by flow cytometry, and measured serum cytokines by enzyme-linked immunosorbent assays. Among the different CHB phases, the serum HBV pgRNA level was highest in the immune tolerant (IT) and immune active (IA) phases. Read More

View Article and Full-Text PDF

Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center.

J Hepatocell Carcinoma 2021 11;8:565-574. Epub 2021 Jun 11.

Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Background: Direct-acting antivirals (DAA) have revolutionized the therapy of chronic hepatitis C (CHC) and have replaced previous PEG-interferon/ribavirin (PEG-IFN/RBV) treatment. Patients with CHC and advanced liver disease are at increased risk for hepatocellular carcinoma (HCC). However, the effects of DAA-based CHC treatment on subsequent HCC incidence remain poorly understood. Read More

View Article and Full-Text PDF

Longitudinal changes in physical and mental health of older adults with chronic hepatitis B infection: Trajectories and predictors.

Prev Med Rep 2021 Sep 2;23:101432. Epub 2021 Jun 2.

Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan.

Despite the increasing health burden of chronic hepatitis B (CHB) in aging populations, little is known about the course of health-related quality of life (HRQoL) changes. We aimed to assess individual-level longitudinal HRQoL changes in elderly patients with CHB and to examine their correlates. A prospective 5. Read More

View Article and Full-Text PDF
September 2021

Autoimmune Hepatitis: Treatment Options and Management Review.

Eyad Gadour

Cureus 2021 Jun 16;13(6):e15682. Epub 2021 Jun 16.

Gastroenterology and Hepatology, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, GBR.

Autoimmune hepatitis (AIH) is an inflammatory pathology of the liver which leads to liver cirrhosis and death if left untreated and affects a large population across the world with no ethnic discrimination. AIH can be asymptomatic or with non-typical clinical presentation. The diagnosis and categorization of AIH are based on the presence of autoantibodies, specific biochemical indices, and histopathological features. Read More

View Article and Full-Text PDF

Autoimmune Hepatitis With Concomitant Pernicious Anemia: A Rare Association.

Cureus 2021 May 15;13(5):e15045. Epub 2021 May 15.

Gastroenterology, Cleveland Clinic Florida, Weston, USA.

The co-occurrence of autoimmune hepatitis (AIH) and pernicious anemia (PA) is extremely rare. We present a case of a 70-year-old woman with AIH who presented for the evaluation of poor appetite and weight loss. Laboratory studies were significant for microcytic anemia, B12, and iron deficiency. Read More

View Article and Full-Text PDF